SCHEMBL2902745

SCHEMBL2902745

CC(C)(C)OC(=O)N1CC(N(CCO)C(=O)OC(C)(C)C)C1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.49
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
HSD11B1 P28845 2/20 0.38
USP2 O75604 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
NAMPT P43490 1/20 0.36
USP30 Q70CQ3 2/20 0.36
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
GPR119 Q8TDV5 1/20 0.36
HPGD P15428 1/20 0.35
JAK2 O60674 1/20 0.35
JAK1 P23458 1/20 0.35
RECQL P46063 1/20 0.34
EPHX1 P07099 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL34474666 0.88 NR1H2 (0.46) NR1H2DDB1CRBNHSD11B1USP2
SCHEMBL13072295 0.86 NR1H2 (0.47) NR1H2DDB1CRBNUSP2SMN1; SMN2
SCHEMBL34474589 0.85 NR1H2 (0.48) NR1H2DDB1CRBNHSD11B1USP2
SCHEMBL18696874 0.83 MEN1 (0.43) NR1H2DDB1CRBNHSD11B1USP2
SCHEMBL15295697 0.83 NR1H2 (0.42) NR1H2DDB1CRBNHSD11B1USP2
SCHEMBL15373109 0.82 NR1H2 (0.41) NR1H2DDB1CRBNHSD11B1USP2
SCHEMBL18154358 0.82 NR1H2 (0.46) NR1H2DDB1CRBNHSD11B1USP2
SCHEMBL2899983 0.82 NR1H2 (0.46) NR1H2DDB1CRBNHSD11B1USP2
SCHEMBL16993007 0.82 NR1H2 (0.51) NR1H2DDB1CRBNHSD11B1USP2
SCHEMBL3380271 0.82 HSD11B1 (0.47) NR1H2HSD11B1USP30MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11117915-B2 Antibacterial aminoglycoside analogs Cipla USA, Inc. (US) 2021-09-14 US disclosed
US-11117915-B2 Antibacterial aminoglycoside analogs Cipla USA, Inc. (US) 2021-09-14 US disclosed
US-20200317709-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS Cipla USA, Inc. 2020-10-08 US disclosed
US-20200317709-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS Cipla USA, Inc. 2020-10-08 US disclosed
CN-106188175-B Treatment of klebsiella pneumoniae infections with antibacterial aminoglycoside compounds 轩竹(北京)医药科技有限公司 2020-08-11 CN disclosed
EP-3150617-B1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS CIPLA USA INC (US) 2020-04-08 EP disclosed
US-9688711-B2 Antibacterial aminoglycoside analogs ACHAOGEN, INC. (US) 2017-06-27 US disclosed
US-9688711-B2 Antibacterial aminoglycoside analogs ACHAOGEN, INC. (US) 2017-06-27 US disclosed
US-9688711-B2 Antibacterial aminoglycoside analogs ACHAOGEN, INC. (US) 2017-06-27 US disclosed
EP-3150617-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS Achaogen, Inc. (US) 2017-04-05 EP disclosed
CN-102481306-A Treatment of urinary tract infections with antibacterial aminoglycoside compounds ACHAOGEN INC 2012-05-30 CN disclosed
WO-2010132777-A2 TREATMENT OF URINARY TRACT INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS ACHAOGEN, INC. (US) 2010-11-18 WO disclosed
WO-2010132770-A1 TREATMENT OF KLEBSIELLA PNEUMONIAE INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS ACHAOGEN, INC. (US) 2010-11-18 WO disclosed
CN-101868472-A Antibacterial aminoglycoside analogs ACHAOGEN INC 2010-10-20 CN disclosed
EP-2217610-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS Achaogen, Inc. (US) 2010-08-18 EP disclosed
US-20100099661-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-22 US disclosed
US-20100099661-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-22 US disclosed
US-20100099661-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-22 US disclosed
WO-2009067692-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2009-05-28 WO disclosed
WO-2009067692-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2009-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200317709-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS MRPL21, MRPL9, NQO2 NR1H2 1577/4885DDB1 2129/4885CRBN 4462/4885
US-20100099661-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS MRPL21, MRPL9, NQO2 NR1H2 1577/4885DDB1 2129/4885CRBN 4462/4885
US-11117915-B2 Antibacterial aminoglycoside analogs MRPL21, MRPL9, NQO2 NR1H2 1577/4885DDB1 2129/4885CRBN 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.